- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
17
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
17 companies
Niagen Bioscience
Market Cap: US$522.2m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$6.37
7D
-1.8%
1Y
3.6%
Catalyst Pharmaceuticals
Market Cap: US$2.9b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$24.18
7D
4.4%
1Y
11.7%
Merck
Market Cap: US$248.9b
Operates as a healthcare company worldwide.
MRK
US$100.26
7D
1.3%
1Y
0.2%
CytomX Therapeutics
Market Cap: US$709.9m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$4.13
7D
6.7%
1Y
259.1%
Incyte
Market Cap: US$18.7b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$98.64
7D
2.0%
1Y
41.3%
Harmony Biosciences Holdings
Market Cap: US$2.3b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$40.51
7D
4.1%
1Y
22.5%
ADMA Biologics
Market Cap: US$4.7b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$19.78
7D
2.0%
1Y
4.2%
Exelixis
Market Cap: US$11.0b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$41.38
7D
-1.9%
1Y
14.7%
Medpace Holdings
Market Cap: US$15.7b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$559.13
7D
1.8%
1Y
59.9%
ACADIA Pharmaceuticals
Market Cap: US$4.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$27.26
7D
1.9%
1Y
57.2%
Puma Biotechnology
Market Cap: US$295.3m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.82
7D
7.8%
1Y
94.0%
BioStem Technologies
Market Cap: US$69.4m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$3.95
7D
-8.8%
1Y
-77.1%
Rigel Pharmaceuticals
Market Cap: US$740.2m
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
RIGL
US$42.48
7D
-2.1%
1Y
121.9%
Halozyme Therapeutics
Market Cap: US$7.3b
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
HALO
US$63.45
7D
0.9%
1Y
32.1%
Oramed Pharmaceuticals
Market Cap: US$122.2m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.08
7D
14.5%
1Y
28.9%
Eli Lilly
Market Cap: US$920.0b
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
LLY
US$1,062.19
7D
6.5%
1Y
36.4%
Earth Science Tech
Market Cap: US$38.3m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.14
7D
4.4%
1Y
8.5%